AquaBounty Technologies (NASDAQ:AQB) Issues Earnings Results, Misses Expectations By $3.13 EPS

AquaBounty Technologies (NASDAQ:AQBGet Free Report) posted its earnings results on Tuesday. The company reported ($3.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($3.13), FiscalAI reports.

AquaBounty Technologies Price Performance

AquaBounty Technologies stock opened at $0.87 on Tuesday. The business has a fifty day moving average price of $0.93 and a 200-day moving average price of $1.14. AquaBounty Technologies has a 1-year low of $0.60 and a 1-year high of $2.95. The stock has a market capitalization of $3.36 million, a price-to-earnings ratio of -1.04 and a beta of 1.29.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of AquaBounty Technologies in a research report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, AquaBounty Technologies has an average rating of “Sell”.

Read Our Latest Stock Report on AQB

Institutional Investors Weigh In On AquaBounty Technologies

An institutional investor recently bought a new position in AquaBounty Technologies stock. Two Sigma Investments LP purchased a new position in shares of AquaBounty Technologies, Inc. (NASDAQ:AQBFree Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 37,565 shares of the company’s stock, valued at approximately $84,000. Two Sigma Investments LP owned about 0.97% of AquaBounty Technologies as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 8.92% of the company’s stock.

About AquaBounty Technologies

(Get Free Report)

AquaBounty Technologies, Inc is a biotechnology company focused on aquaculture innovation through the development and commercialization of genetically engineered fish. Its flagship product, AquAdvantage Salmon, is an Atlantic salmon strain enhanced with a growth hormone gene that enables faster growth and more efficient feed conversion compared with conventional farmed salmon. By integrating biotechnology into seafood production, AquaBounty aims to address global protein demand while reducing the environmental footprint associated with marine aquaculture.

Founded in 1991, AquaBounty is headquartered in Maynard, Massachusetts, and operates a state-of-the-art, land-based incubation and grow-out facility in Panama.

Read More

Earnings History for AquaBounty Technologies (NASDAQ:AQB)

Receive News & Ratings for AquaBounty Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AquaBounty Technologies and related companies with MarketBeat.com's FREE daily email newsletter.